Genedrive PLC Collaboration to automate COVID-19 PCR testing (9991U)
04 August 2020 - 4:00PM
UK Regulatory
TIDMGDR
RNS Number : 9991U
Genedrive PLC
04 August 2020
The information contained within this Announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this Announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
genedrive plc
("genedrive" or the "Company")
Beckman Coulter collaboration to automate high throughput
SARS-CoV-2 PCR testing
genedrive plc (LSE: GDR), the near patient molecular diagnostics
company, announces that it has entered into a collaboration with
Beckman Coulter Life Sciences ("Beckman Coulter") to fully automate
the entire laboratory PCR testing process for COVID-19. The two
companies are working to combine and validate the Genedrive(R) 96
SARS-CoV-2 Kit on the Biomek i7 automated workstation with saliva
samples extracted using Beckman Coulter's RNAdvance viral
extraction chemistry.
The freeze dried bead chemistry of the Genedrive(R) 96
SARS-CoV-2 test is ideally suited for use on high throughput
robotic platforms like the Biomek i7. Stable at room temperature
for 4 hours after unsealing, many Genedrive(R) 96 SARS-CoV-2 Kit
96-well plates can be left arrayed and open in the laboratory
environment during the set-up process. The ready-to-go nature of
the test bead also removes the fluid dispensing steps required in
other assays, increasing the overall throughput of the Biomex i7
compared to using a liquid based test set-up. Accordingly, once
validated, Beckman Coulter estimates that this new turnkey solution
could process circa 1,000 PCR samples per Biomek installed during a
standard 8-hour working day, using just a 0.5 full-time-equivalent
in technician time for processing.
Genedrive has already completed initial evaluation of Beckman
Coulter's RNA extraction chemistry to confirm compatibility with
the Genedrive 96 SARS-CoV-2 test. Further work is ongoing to
validate clinical saliva samples which are a very relevant sample
type for applications such as high volume occupational screening.
Beckman's RNAdvance Viral XP has already been listed as an
extraction method for swab samples for use with the Centers for
Disease Control's EUA-authorized COVID-19 test in FDA's FAQ on
testing for SARS-CoV-2.
Greg Milosevich, President at Beckman Coulter Life Sciences,
said "The integration of Beckman Coulter Life Sciences' and
genedrive's technologies produces a formidable workhorse solution
for specialized laboratories looking to establish new or next level
laboratory automation with labor cost reduction. Our ability to
fully integrate the RNA extraction process on the Biomek while
simultaneously preparing the plates for analysis is a critical step
forward in advancing COVID testing workflows. Speed up the testing
workflow, reduce labor time and costs. This is the goal of our
collaboration with Genedrive and we are excited to be bringing this
solution forward to the market."
David Budd, Chief Executive Officer of genedrive plc, said "We
are very pleased to have the opportunity to work with Beckman
Coulter in delivering an innovative high throughput COVID-19 PCR
solution. It's been our focus to work with a top tier, high
throughput lab automation partner like Beckman to drive uptake of
our test and further differentiate our unique capabilities in the
market. The combination of our ready to use chemistry with robotics
and on-board RNA extraction would give laboratories a unique and
rapid workflow that can achieve impressive throughput and result
turnaround times. We are both working to have the ongoing
validation completed in approximately 6 weeks, with initial
introduction in the USA at an already identified clinical
laboratory."
The integrated Genedrive/Beckman Coulter solution will be
introduced in selected, relevant geographies subject to validation
and any required regulatory approvals.
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler:
CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice
Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on market for the detection of
HCV, certain military biological targets, and has tests in
development for tuberculosis (mTB). The Company recently announced
the development of a high throughput SARS-CoV-2 assay and a
Genedrive(R) Point of Care version of the assay, both based on
Genedrive(R) PCR chemistry.
About Beckman Coulter Life Sciences https://www.beckman.com/
Beckman Coulter Life Sciences has helped establish test sites
globally for a broad range of customer sizes and testing
requirements. We are dedicated to advancing and optimizing the
laboratory. For more than 80 years, we have been a trusted partner
for laboratory professionals, helping to advance scientific
research and patient care. We have a vital role: our focus on
innovation, reliability and efficiency has led us to become the
partner of choice for clinical, research and industrial customers
around the globe.
RNAdvance Viral XP is listed as an extraction method for use
with the Centers for Disease Control's EUA-authorized COVID-19 test
referenced in FDA's FAQ on testing for SARS-CoV-2. Other than this
designation, RNAdvance Viral XP is for research use, and not
intended for diagnostic purposes
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGREAPPDEASEEFA
(END) Dow Jones Newswires
August 04, 2020 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024
